FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032746238> ?p ?o ?g. }

• W2032746238 abstract "Background: The median survival for patients (pts) receiving trastuzumab (T) in the metastatic setting is approximately 3 years. There are limited data on real world use and outcomes in T treated pts who live longer than 3 years. The objective of this study was to identify and characterize pts with HER2+ MBC who initiated treatment with T (alone or in combination) in a community setting and to determine their treatment patterns and outcomes, including duration of treatment, overall survival (OS) and time to permanent discontinuation of T. Methods: A retrospective observational study was performed using the IKnowMed electronic medical record (EMR) used by the US Oncology Network with the primary time period of 2007 through Dec. 2012. Eligible pts had at least 2 visits at practice locations with full EMR capability. Pts on T when the EMR was implemented had chart review to determine the dates of diagnosis and start of T treatment. Results: The study population included 1856 women with HER2+ MBC who started T (alone or in combination with chemotherapy or hormonal therapy); 873 presented with MBC and 983 developed recurrence following diagnosis of early-stage disease. The median age was 58, range 23 to 96, 59% had ER+ cancer, 64% were postmenopausal and 35% had multiple sites of disease at presentation. Median OS for the entire group was 40.9 months and the median time to permanent discontinuation of T was slightly less, at 39.9 months. Interestingly, the median OS and duration of T use were similar in the recurrent MBC population and in the population who presented with de novo MBC. The proportion of pts receiving T and OS by year are presented (Table). Thirty-two percent of pts are still alive at 6 years, with 17% continuing to receive T. Ongoing analysis will evaluate whether there are pt and treatment characteristics that may predict for longer term OS. Conclusions: Using an EMR database we identified 1856 women with HER2+ MBC who initiated treatment with T (alone or in combination) with one third still alive at 5 years and 27% still on T. Future research that focuses on understanding the characteristics of this population can potentially improve care for women with HER2+ MBC with T and newer anti-HER2 agents. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-16-09." @default.
• W2032746238 created "2016-06-24" @default.
• W2032746238 creator A5009023062 @default.
• W2032746238 creator A5011194371 @default.
• W2032746238 creator A5032187510 @default.
• W2032746238 creator A5040674403 @default.
• W2032746238 creator A5042131438 @default.
• W2032746238 creator A5064635138 @default.
• W2032746238 creator A5072015843 @default.
• W2032746238 creator A5072830427 @default.
• W2032746238 creator A5080113617 @default.
• W2032746238 date "2013-12-15" @default.
• W2032746238 modified "2023-09-27" @default.
• W2032746238 title "Abstract P2-16-09: Retrospective analysis of long-term survivors with HER2+ metastatic breast cancer (MBC) treated with trastuzumab in a community setting" @default.
• W2032746238 doi "https://doi.org/10.1158/0008-5472.sabcs13-p2-16-09" @default.
• W2032746238 hasPublicationYear "2013" @default.
• W2032746238 type Work @default.
• W2032746238 sameAs 2032746238 @default.
• W2032746238 citedByCount "0" @default.
• W2032746238 crossrefType "proceedings-article" @default.
• W2032746238 hasAuthorship W2032746238A5009023062 @default.
• W2032746238 hasAuthorship W2032746238A5011194371 @default.
• W2032746238 hasAuthorship W2032746238A5032187510 @default.
• W2032746238 hasAuthorship W2032746238A5040674403 @default.
• W2032746238 hasAuthorship W2032746238A5042131438 @default.
• W2032746238 hasAuthorship W2032746238A5064635138 @default.
• W2032746238 hasAuthorship W2032746238A5072015843 @default.
• W2032746238 hasAuthorship W2032746238A5072830427 @default.
• W2032746238 hasAuthorship W2032746238A5080113617 @default.
• W2032746238 hasConcept C121608353 @default.
• W2032746238 hasConcept C126322002 @default.
• W2032746238 hasConcept C141071460 @default.
• W2032746238 hasConcept C143998085 @default.
• W2032746238 hasConcept C146357865 @default.
• W2032746238 hasConcept C151730666 @default.
• W2032746238 hasConcept C167135981 @default.
• W2032746238 hasConcept C195910791 @default.
• W2032746238 hasConcept C2775930923 @default.
• W2032746238 hasConcept C2778715236 @default.
• W2032746238 hasConcept C2779786085 @default.
• W2032746238 hasConcept C2908647359 @default.
• W2032746238 hasConcept C530470458 @default.
• W2032746238 hasConcept C71924100 @default.
• W2032746238 hasConcept C86803240 @default.
• W2032746238 hasConcept C99454951 @default.
• W2032746238 hasConceptScore W2032746238C121608353 @default.
• W2032746238 hasConceptScore W2032746238C126322002 @default.
• W2032746238 hasConceptScore W2032746238C141071460 @default.
• W2032746238 hasConceptScore W2032746238C143998085 @default.
• W2032746238 hasConceptScore W2032746238C146357865 @default.
• W2032746238 hasConceptScore W2032746238C151730666 @default.
• W2032746238 hasConceptScore W2032746238C167135981 @default.
• W2032746238 hasConceptScore W2032746238C195910791 @default.
• W2032746238 hasConceptScore W2032746238C2775930923 @default.
• W2032746238 hasConceptScore W2032746238C2778715236 @default.
• W2032746238 hasConceptScore W2032746238C2779786085 @default.
• W2032746238 hasConceptScore W2032746238C2908647359 @default.
• W2032746238 hasConceptScore W2032746238C530470458 @default.
• W2032746238 hasConceptScore W2032746238C71924100 @default.
• W2032746238 hasConceptScore W2032746238C86803240 @default.
• W2032746238 hasConceptScore W2032746238C99454951 @default.
• W2032746238 hasLocation W20327462381 @default.
• W2032746238 hasOpenAccess W2032746238 @default.
• W2032746238 hasPrimaryLocation W20327462381 @default.
• W2032746238 isParatext "false" @default.
• W2032746238 isRetracted "false" @default.
• W2032746238 magId "2032746238" @default.
• W2032746238 workType "article" @default.